DNA replication stress and cancer chemotherapy

Kitao, Hiroyuki; Iimori, Makoto; Kataoka, Yuki; Wakasa, Takeshi; Tokunaga, Eriko; Saeki, Hiroshi; Oki, Eiji; Maehara, Yoshihiko

doi:10.1111/cas.13455

Cited by 89 publications

(73 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The transcriptionally active genes, especially those involved in developmental regulation and the cell cycle, interact in the nucleus with the nuclear porin [42]. It is also known that DNA replication disorders cause genomic instability and confer genetic diversity during tumorigenesis [43], explaining how the above pathways may identify effective treatment strategies for LUAD.…”

Section: Discussionmentioning

confidence: 99%

A signature related to lung adenocarcinoma prognosis: A study based on TCGA database

Wang¹,

Zhang²,

Zhang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The intrinsic molecular subtypes of lung adenocarcinoma (LUAD) impact clinical treatment decision-making, but the molecular mechanisms are still unclear. Therefore, we aimed to identify sensitive biomarkers to evaluate LUAD patient prognosis. Methods: Differentially expressed RNAs from LUAD patients were obtained from The Cancer Genome Atlas (TCGA) database and they were used to construct a competitive endogenous RNA (ceRNA) network. Based on the examination of clinical data, long noncoding RNAs (lncRNAs) and mRNAs in the network were selected by univariate and multivariate Cox regression analysis. Finally, functional enrichment analysis was used to reveal prognostic signatures based on the classification into high and low-risk groups, survival analysis, and an independence test. Results: The ceRNA network consisted of 21 mRNAs, 53 lncRNAs, and 8 miRNAs that were selected from the differentially expressed RNAs identified. Next, based on univariate and multivariate Cox regression analysis, a prognostic signature, including two mRNAs (HOXA10 and CBX2) and four lncRNAs (LINC00460, LINC00330, DGCR5, and C14orf132) was constructed. Eventually, survival analysis showed that significant differences in survival rates between high and low-risk groups and the area under the curve (AUC) for three‐year survival was 0.714. Compared with clinical risk factors, including age, pathological stage, and TNM stage, our risk score had a higher prognostic value. Conclusion: By screening from a ceRNA network, we constructed a signature, including two mRNAs (HOXA10 and CBX2) and four lncRNAs (LINC00460, LINC00330, DGCR5, and C14orf132), that can be utilized as a prognostic biomarker in LUAD. This signature may provide options for clinical treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

A signature related to lung adenocarcinoma prognosis: A study based on TCGA database

Wang¹,

Zhang²,

Zhang³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Research in DNA replication is also progressing, and its relationship to cancer development is becoming clearer. Dysregulation of DNA replication can lead to genomic instability, and an important feature of cancer formation is this instability [26] . Cancer may be related to errors in DNA at the replication stage and the combined effects of changes caused by environmental factors and mutations in genetic information [27] .…”

Section: Discussionmentioning

confidence: 99%

CCT6A, a Novel Prognostic Biomarker for Ewing's Sarcoma

Jiang

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Ewing's sarcoma (ES) is the second most prevalent malignancy among bone tissue tumors, and there is no adequate prognosis biomarker. The protein encoded by CCT6A is a molecular chaperone. Early studies have suggested that CCT6A is involved in the development of many cancers, however, there is no clear evidence of a role for CCT6A in ES.Methods: In this study, we performed a bioinformatics analysis of 32 Ewing sarcoma specimens from the GSE17618 dataset for differences in gene expression and overall survival, event-free survival, and gene expression in different subgroups. Results: After three screenings, we identified CCT6A as highly correlated with Ewing's sarcoma prognosis. Survival analysis showed low overall survival (OS) for CCT6A high expression (P=0.024). On the other hand, Cox regression analysis showed that CCT6A expression, event-free survival (EFS), and age were strongly associated with the prognosis of Ewing sarcoma, identified as independent poor prognostic biomarkers. (CCT6A: P=0.015; Age: P-value=0.026; EFS: P-value=0.001). Conclusion: The expression level of CCT6A is strongly associated with the prognosis of Ewing's sarcoma. High expression of the CCT6A gene may serve as a biomarker for poor prognosis in patients with Ewing's sarcoma.

show abstract

“…Dysregulation of DNA replication can lead to genomic instability, and an important feature of cancer formation is this instability [26] . Cancer may be related to errors in DNA at the replication stage and the combined effects of changes caused by environmental factors and mutations in genetic information [27] .…”

Section: Discussionmentioning

confidence: 99%

CCT6A, a novel prognostic biomarker for Ewing's sarcoma

Jiang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Ewing's sarcoma (ES) is the second most prevalent malignancy among bone tissue tumors, and there is no adequate prognosis biomarker. The protein encoded by CCT6A is a molecular chaperone. Early studies have suggested that CCT6A is involved in the development of many cancers, however, there is no clear evidence of a role for CCT6A in ES. Methods In this study, we performed a bioinformatics analysis of 32 Ewing sarcoma specimens from the GSE17618 dataset for differences in gene expression and overall survival, event-free survival, and gene expression in different subgroups. Results After three screenings, we identified CCT6A as highly correlated with Ewing's sarcoma prognosis. Survival analysis showed low overall survival (OS) for CCT6A high expression (P = 0.024). On the other hand, Cox regression analysis showed that CCT6A expression, event-free survival (EFS), and age were strongly associated with the prognosis of Ewing sarcoma, identified as independent poor prognostic biomarkers. (CCT6A: P = 0.015; Age: P-value = 0.026; EFS: P-value = 0.001). Conclusion The expression level of CCT6A is strongly associated with the prognosis of Ewing's sarcoma. High expression of the CCT6A gene may serve as a biomarker for poor prognosis in patients with Ewing's sarcoma.

show abstract

DNA replication stress and cancer chemotherapy

Cited by 89 publications

References 67 publications

A signature related to lung adenocarcinoma prognosis: A study based on TCGA database

A signature related to lung adenocarcinoma prognosis: A study based on TCGA database

CCT6A, a Novel Prognostic Biomarker for Ewing's Sarcoma

CCT6A, a novel prognostic biomarker for Ewing's sarcoma

Contact Info

Product

Resources

About